← Back to Screener
PLUS THERAPEUTICS, Inc. Common Stock (PSTV)
Price$5.41
Value ScoreD
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-72.45%
Price vs S&P 500 (4W)-11.59%
VGM Score35.57
Market Capitalization$37.24M
All Metrics
Book Value / Share (Quarterly)$1.74
P/TBV (Annual)19.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)187.22%
Cash Flow / Share (Quarterly)$-3.17
Price vs S&P 500 (YTD)-65.93%
Gross Margin (TTM)74.77%
Net Profit Margin (TTM)-230.24%
EPS (TTM)$-2.50
10-Day Avg Trading Volume0.13M
EPS Excl Extra (TTM)$-2.50
Revenue Growth (5Y)77.01%
EPS (Annual)$-7.19
ROI (Annual)-471.68%
Gross Margin (Annual)64.36%
Net Profit Margin (5Y Avg)-2577.63%
Cash / Share (Quarterly)$2.20
Revenue Growth QoQ (YoY)-2.93%
ROA (Last FY)-137.13%
Revenue Growth TTM (YoY)-0.46%
EBITD / Share (TTM)$-2.98
ROE (5Y Avg)-441.80%
Operating Margin (TTM)-364.36%
Cash Flow / Share (Annual)$-3.76
P/B Ratio3.11x
P/B Ratio (Quarterly)2.33x
Net Income / Employee (Annual)$-799,500
EV / Revenue (TTM)6.73x
Net Interest Coverage (TTM)-2.66x
ROA (TTM)-73.13%
EPS Incl Extra (Annual)$-7.19
Current Ratio (Annual)1.23x
Quick Ratio (Quarterly)2.12x
3-Month Avg Trading Volume0.30M
52-Week Price Return-32.21%
Revenue / Employee (TTM)$185,100
Tangible BV / Share (Quarterly)$1.70
P/S Ratio (Annual)7.14x
Asset Turnover (Annual)0.32x
52-Week High$23.43
Operating Margin (5Y Avg)-2593.87%
EPS Excl Extra (Annual)$-7.19
CapEx CAGR (5Y)-32.83%
Tangible BV CAGR (5Y)7.60%
26-Week Price Return-64.52%
Quick Ratio (Annual)1.12x
13-Week Price Return-27.19%
Total Debt / Equity (Annual)0.19x
Current Ratio (Quarterly)2.27x
Enterprise Value$34.88M
Revenue / Share Growth (5Y)10.87%
Asset Turnover (TTM)0.32x
Book Value / Share Growth (5Y)-69.23%
Revenue / Employee (Annual)$186,200
Inventory Turnover (Annual)1.44x
Pretax Margin (Annual)-429.43%
Cash / Share (Annual)$1.55
3-Month Return Std Dev124.28%
Gross Margin (5Y Avg)66.98%
Net Income / Employee (TTM)$-426,100
ROE (Last FY)-560.21%
Net Interest Coverage (Annual)-0.48x
EPS Basic Excl Extra (Annual)$-7.19
P/FCF (TTM)38.39x
Receivables Turnover (TTM)0.53x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$-2.50
Receivables Turnover (Annual)0.51x
ROI (TTM)-187.43%
P/S Ratio (TTM)7.19x
Pretax Margin (5Y Avg)-2577.63%
Revenue / Share (Annual)$1.68
Tangible BV / Share (Annual)$0.66
Price vs S&P 500 (52W)-56.57%
Year-to-Date Return-57.77%
5-Day Price Return-5.09%
EPS Normalized (Annual)$-7.19
ROA (5Y Avg)-119.13%
Net Profit Margin (Annual)-429.43%
Month-to-Date Return-7.04%
Cash Flow / Share (TTM)$-5.64
EBITD / Share (Annual)$-4.77
Operating Margin (Annual)-293.46%
LT Debt / Equity (Annual)0.59x
ROI (5Y Avg)-179.16%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.50
P/TBV (Quarterly)2.39x
P/B Ratio (Annual)17.62x
Inventory Turnover (TTM)0.74x
Pretax Margin (TTM)-230.24%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)-35.44%
Beta1.44x
Revenue / Share (TTM)$0.78
ROE (TTM)-198.48%
52-Week Low$2.90
vGradeD
gGradeC
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.05est. -0.90
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.09
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PSTVPLUS THERAPEUTICS, Inc. Common Stock | D | C | D | $5.41 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Plus Therapeutics is a clinical-stage pharmaceutical company developing treatments for CNS cancers, including recurrent glioblastoma and leptomeningeal metastases. Its lead candidate, rhenium-186 obisbemeda, is a targeted radiotherapeutic designed for cancers with limited treatment options, including pediatric brain cancers.